UAE investors chase $39.4 billion GLP-1 opportunity as local healthcare stocks lag

UAE-based investors are shifting capital into GLP-1 drug makers Novo Nordisk and Eli Lilly, targeting a $39.4 billion global market while domestically listed healthcare equities trail broader indices by 8-12 percentage points, Zawya reported on 7 April 2026.

The gap reflects a preference among Gulf capital allocators for offshore pharmaceutical growth over local hospital and insurance stocks, which face margin compression from DHA fee schedule revisions, rising staffing costs in a tight nursing labour market, and a saturated primary care sector in Dubai and Abu Dhabi.

Why GLP-1 drugs attract Gulf capital

GLP-1 receptor agonists, led by Novo Nordisk's semaglutide (Ozempic, Wegovy) and Eli Lilly's tirzepatide (Mounjaro, Zepbound), are the fastest-growing drug class by revenue in recent pharmaceutical history. Global GLP-1 sales hit $39.4 billion in trailing 12-month revenue. Goldman Sachs and Morgan Stanley project the category will exceed $100 billion by 2030 as indications expand beyond type 2 diabetes and obesity into cardiovascular risk reduction, MASH (metabolic dysfunction-associated steatohepatitis), and chronic kidney disease.

The UAE has a strong domestic demand case. The International Diabetes Federation estimates diabetes prevalence among UAE adults at 16.3%, one of the highest rates globally. Obesity affects 31% of the adult population, according to World Health Organization data. Both conditions are primary indications for GLP-1 therapies. DHA and the Department of Health Abu Dhabi (DOH) have both expanded insurance formulary coverage for weight management medications since mid-2024, increasing domestic prescription volumes.

Local healthcare stocks under pressure

Pure Health, the Abu Dhabi hospital group, has seen its share price retreat from 2024 highs as post-pandemic testing revenues normalized. Aster DM Healthcare delisted its UAE entity in 2023, and remaining listed operators face headwinds from DHA fee schedule revisions, rising staffing costs, and compliance expenditure tied to MOHAP's mandatory electronic health record integration deadline in 2026.

Healthcare as a sector on the ADX has underperformed the broader index by 8-12 percentage points over the past 12 months, pushing yield-seeking investors toward pharmaceutical equities listed in Copenhagen and New York.

What operators should watch

For UAE healthcare executives, the GLP-1 wave carries operational consequences beyond stock market flows:

• CFOs should monitor insurance reimbursement policy for GLP-1 prescriptions. DHA's Essential Benefits Plan and DOH's Thiqa programme are both reviewing coverage tiers for semaglutide and tirzepatide, with formulary decisions expected by Q3 2026.
• Medical directors face prescribing volume increases. Endocrinology and internal medicine departments at UAE hospitals report GLP-1 prescription volumes up 40-60% year-on-year, straining supply chains and requiring updated clinical protocols for patient monitoring.
• COOs running weight management or metabolic health clinics should plan for capacity pressure as patient demand rises alongside expanded insurance coverage.
• Startup founders in digital therapeutics or remote patient monitoring have an opening: GLP-1 patients require ongoing follow-up for gastrointestinal side effects, dose titration, and nutritional counselling, all suited to virtual care delivery.

The gap between investor enthusiasm for GLP-1 drug makers and scepticism toward UAE hospital operators may narrow if local providers capture more of the metabolic health revenue stream. Clinics that build structured obesity and diabetes programmes around GLP-1 therapies, rather than treating the drugs as standalone prescriptions, stand to improve both clinical outcomes and revenue per patient. DHA's forthcoming obesity management framework, expected in late 2026, will set the benchmark for how these programmes are structured and reimbursed across the emirates.